Minjuvi (Tafasitamab)

Tafasitamab, the active ingredient in Minjuvi, is a monoclonal antibody presented as an intravenous solution for intravenous use. It belongs to the antineoplastic (oncology) therapeutic class and is indicated for adult patients with relapsed or refractory diffuse large B‑cell lymphoma, usually administered together with lenalidomide.

GNH USA supplies Minjuvi as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to oncology centres, hospitals and specialty pharmacies worldwide under strict quality standards. The supply chain includes temperature‑controlled logistics to maintain product integrity.

Minjuvi is a monoclonal antibody indicated for CD19‑positive B‑cell lymphoma indications, primarily in the diffuse large B‑cell lymphoma disease family. - Relapsed or refractory diffuse large B‑cell lymphoma (DLBCL): used in combination with lenalidomide to achieve disease control. - Adult patients with DLBCL who are ineligible for stem‑cell transplant: offers a non‑transplant therapeutic option. - CD19‑positive B‑cell lymphomas under clinical evaluation: being studied as part of combination regimens to expand treatment options.

Adverse reactions have been reported with Minjuvi and are categorized by frequency.

Common Side Effects: - Infusion‑related reactions: fever, chills, or flushing during or shortly after administration. - Cytopenias: decreased neutrophil or platelet counts. - Fatigue: general tiredness or weakness. - Nausea: mild to moderate gastrointestinal upset.

Serious or Rare Side Effects: - Severe infections: opportunistic or bacterial infections requiring hospitalization. - Hepatotoxicity: elevated liver enzymes or liver injury. - Hypersensitivity reactions: anaphylaxis or severe allergic responses. - Tumor lysis syndrome: rapid tumor breakdown leading to metabolic disturbances.

Before initiating therapy, clinicians should assess patient suitability and monitor for known risks. - Baseline labs: obtain complete blood count and liver function tests prior to first dose. - Infection monitoring: watch for signs of infection and manage promptly. - Concomitant lenalidomide: adjust dosing and monitor for additive cytopenias. - Pregnancy and lactation: discuss potential risks as safety data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Tafasitamab may interact with other agents that affect immune function or hematologic parameters.

Major Interactions (Avoid): - Live vaccines: increased risk of infection; avoid administration during treatment. - Strong immunosuppressants: may diminish therapeutic efficacy and increase infection risk.

Moderate Interactions (Monitor Closely): - CYP450 substrates: lenalidomide does not significantly affect metabolism, but monitor for additive toxicity. - Anticoagulants: monitor bleeding parameters if thrombocytopenia occurs. - Other monoclonal antibodies: assess overlapping toxicities and adjust monitoring accordingly.